Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities

Pediatric Cardiology

Volumn 31, Issue 6, 2010, Pages 834-842

  Manlhiot, Cedric ^a   Brandão, Leonardo R ^a   Somji, Zeeshanefatema ^a   Chesney, Amy L ^a   MacDonald, Catherine ^a   Gurofsky, Rebecca C ^a   Sabharwal, Tarun ^a   Chahal, Nita ^a   McCrindle, Brian W ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Anticoagulants; Coronary disease; Kawasaki disease; Pediatric; Thrombosis

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHILD; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; HEART INFARCTION; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; REMISSION; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; COMPLICATION; CORONARY DISEASE; DOSE RESPONSE; ECHOCARDIOGRAPHY; ECHOGRAPHY; FOLLOW UP; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; CHILD, PRESCHOOL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 77955560613     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-010-9715-8     Document Type: Article

References (43)

1. M Albisetti AK Chan BW McCrindle D Wong P Vegh M Adams, et al. 2003 Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease Blood Coagul Fibrinolysis 14 181 186 10.1097/00001721- 200302000-00010 1:CAS:528:DC%2BD3sXhvFCjsb4%3D 12632029
2. M Andrew V Marzinotto LA Brooker M Adams J Ginsberg R Freedom, et al. 1994 Oral anticoagulation therapy in pediatric patients: a prospective study Thromb Haemost 71 265 269 1:STN:280:DyaK2czgt1KhtA%3D%3D 8029786
3. C Barnes F Newall V Ignjatovic P Wong F Cameron G Jones, et al. 2005 Reduced bone density in children on long-term warfarin Pediatr Res 57 578 581 10.1203/01.PDR.0000155943.07244.04 15695604
4. MM Bonduel 2006 Oral anticoagulation therapy in children Thromb Res 118 85 94 10.1016/j.thromres.2004.12.017 1:CAS:528:DC%2BD28XkslSntrc%3D 16709477
5. JP Boyle RH Smart JK Shirey 1964 Heparin in the treatment of chronic obstructive bronchopulmonary disease Am J Cardiol 14 25 28 10.1016/0002-9149(64) 90100-6 1:STN:280:DyaF2c7jsVyrtQ%3D%3D 14176885
6. JC Burns MP Glode SH Clarke J Wiggins Jr WE Hathaway 1984 Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms J Pediatr 105 206 211 10.1016/S0022-3476(84)80114-6 1:STN:280:DyaL2c3mslWnsg%3D%3D 6235335
7. A de Zorzi SD Colan K Gauvreau AL Baker RP Sundel JW Newburger 1998 Coronary artery dimensions may be misclassified as normal in Kawasaki disease J Pediatr 133 254 258 10.1016/S0022-3476(98)70229-X 9709715
8. JA Delaney L Opatrny JM Brophy S Suissa 2007 Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding CMAJ 177 347 351 17698822
9. D Dix M Andrew V Marzinotto K Charpentier S Bridge P Monagle, et al. 2000 The use of low molecular weight heparin in pediatric patients: a prospective cohort study J Pediatr 136 439 445 10.1016/S0022-3476(00)90005-2 1:CAS:528:DC%2BD3cXivFOgt7w%3D 10753240
10. E Elsayed RC Becker 2003 The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development J Thromb Thrombolysis 15 11 18 10.1023/A:1026184100030 1:CAS:528:DC%2BD3sXotVCksL0%3D 14574071
11. T Hidaka M Nakano T Ueta Y Komatsu M Yamamoto 1983 Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease J Pediatr 102 94 96 10.1016/S0022-3476(83)80300-X 1:STN:280:DyaL3s%2FosFWmug%3D%3D 6401332
12. J Hirsh J Dalen DR Anderson L Poller H Bussey J Ansell, et al. 2001 Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 119 Suppl 8S 21S 10.1378/chest.119.1-suppl.8S 1:CAS:528:DC%2BD3MXhtlamsro%3D 11157640
13. H Kato T Sugimura T Akagi N Sato K Hashino Y Maeno, et al. 1996 Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients Circulation 94 1379 1385 1:STN:280:DyaK28vitVaqtQ%3D%3D 8822996
14. AA Khorana A Sahni OD Altland CW Francis 2003 Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight Arterioscler Thromb Vasc Biol 23 2110 2115 10.1161/01.ATV.0000090671.56682.D7 1:CAS:528:DC%2BD3sXoslWksLw%3D 12920044
15. Y Kuramochi T Ohkubo N Takechi D Fukumi Y Uchikoba S Ogawa 2000 Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease Pediatr Int 42 470 475 10.1046/j.1442-200x.2000.01270.x 1:STN:280:DC%2BD3crgslOjsw%3D%3D 11059533
16. S Kurotobi T Nagai N Kawakami T Sano 2002 Coronary diameter in normal infants, children and patients with Kawasaki disease Pediatr Int 44 1 4 10.1046/j.1442-200X.2002.01508.x 11982862
17. R Lever JR Hoult CP Page 2000 The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro Br J Pharmacol 129 533 540 10.1038/sj.bjp.0703099 1:CAS:528:DC%2BD3cXht1yntrw%3D 10711352
18. DM Levy ED Silverman MP Massicotte BW McCrindle RS Yeung 2005 Long-term outcomes in patients with giant aneurysms secondary to Kawasaki disease J Rheumatol 32 928 934 15868632
19. C Manlhiot K Millar F Golding BW McCrindle 2010 Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease Pediatr Cardiol 31 242 249 10.1007/s00246-009-9599-7 20024653
20. BW McCrindle 2004 Cardiovascular complications-Coronary artery structure and function Prog Pediatr Cardiol 19 147 152 10.1016/j.ppedcard.2004.08.008
21. P Monagle AD Michelson E Bovill M Andrew 2001 Antithrombotic therapy in children Chest 119 Suppl 344S 370S 10.1378/chest.119.1-suppl.344S 1:CAS:528:DC%2BD3MXhtlams7Y%3D 11157659
22. Monagle P, Chan AKC, Massicotte P, deVeber G (2005) Andrew's handbook of pediatric thromboembolism and stroke. Decker, Hamilton, Ontario, Canada
23. P Monagle E Chalmers A Chan G DeVeber F Kirkham P Massicotte, et al. 2008 Antithrombotic therapy in neonates and children: American college of chest physicians evidence-based clinical practice guidelines, 8th edn Chest 133 Suppl 887S 968S 10.1378/chest.08-0762 1:CAS:528:DC%2BD1cXptVKhsLs%3D 18574281
24. Y Nakamura H Yanagawa K Harada H Kato T Kawasaki 2000 Mortality among persons with a history of Kawasaki disease in Japan: existence of cardiac sequelae elevated the mortality J Epidemiol 10 372 375 1:STN:280: DC%2BD3M7ktFaltA%3D%3D 11210105
25. Y Nakamura E Aso M Yashiro R Uehara M Watanabe M Tajimi, et al. 2005 Mortality among persons with a history of Kawasaki disease in Japan: can paediatricians safely discontinue follow-up of children with a history of the disease but without cardiac sequelae? Acta Paediatr 94 429 434 16092456
26. MC Nash V Shah MJ Dillon 1995 Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease Clin Exp Immunol 101 13 17 1:CAS:528:DyaK2MXnsF2ktb0%3D 7542571
27. JW Newburger M Takahashi MA Gerber MH Gewitz LY Tani JC Burns, et al. 2004 Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association Pediatrics 114 1708 1733 10.1542/peds.2004- 2182 15574639
28. A Niboshi K Hamaoka K Sakata N Yamaguchi 2008 Endothelial dysfunction in adult patients with a history of Kawasaki disease Eur J Pediatr 167 189 196 10.1007/s00431-007-0452-9 1:CAS:528:DC%2BD2sXhsVKgt7%2FN 17345094
29. Z Onouchi K Hamaoka K Sakata S Ozawa I Shiraishi T Itoi, et al. 2005 Long-term changes in coronary artery aneurysms in patients with Kawasaki disease: comparison of therapeutic regimens Circ J 69 265 272 10.1253/circj.69.265 1:CAS:528:DC%2BD2MXis1Wktbc%3D 15731529
30. T Sabharwal C Manlhiot SM Benseler PN Tyrrell N Chahal RS Yeung, et al. 2009 Comparison of factors associated with coronary artery dilation only versus coronary artery aneurysms in patients with Kawasaki disease Am J Cardiol 104 1743 1747 10.1016/j.amjcard.2009.07.062 19962487
31. UI Schwarz MD Ritchie Y Bradford C Li SM Dudek A Frye-Anderson, et al. 2008 Genetic determinants of response to warfarin during initial anticoagulation N Engl J Med 358 999 1008 10.1056/NEJMoa0708078 1:CAS:528:DC%2BD1cXjtVSrsLs%3D 18322281
32. W Streif M Andrew V Marzinotto P Massicotte AK Chan JA Julian, et al. 1999 Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients Blood 94 3007 3014 1:CAS:528:DyaK1MXntVSrsbg%3D 10556183
33. Y Sugahara M Ishii H Muta M Iemura T Matsuishi H Kato 2008 Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease Pediatr Cardiol 29 398 401 10.1007/s00246-007-9132-9 18027010
34. A Suzuki T Kamiya Y Arakaki Y Kinoshita K Kimura 1994 Fate of coronary arterial aneurysms in Kawasaki disease Am J Cardiol 74 822 824 10.1016/0002-9149(94)90446-4 1:STN:280:DyaK2M%2FivFSmtQ%3D%3D 7942561
35. A Suzuki S Miyagawa-Tomita M Nakazawa C Yutani 2000 Remodeling of coronary artery lesions due to Kawasaki disease: comparison of arteriographic and immunohistochemical findings Jpn Heart J 41 245 256 10.1536/jhj.41.245 1:STN:280:DC%2BD3cvjvVKhsQ%3D%3D 10987345
36. M Takahashi W Mason AB Lewis 1987 Regression of coronary aneurysms in patients with Kawasaki syndrome Circulation 75 387 394 1:STN:280: DyaL2s7gtlGjuw%3D%3D 3802442
37. M Takahashi 1996 Management of giant coronary aneurysms due to Kawasaki syndrome ACC Curr J Rev 5 74 76 10.1016/1062-1458(96)82497-4
38. E Tsuda T Kamiya K Kimura Y Ono S Echigo 2002 Coronary artery dilatation exceeding 4.0 mm during acute Kawasaki disease predicts a high probability of subsequent late intima-medial thickening Pediatr Cardiol 23 9 14 10.1007/s00246-001-0004-4 1:STN:280:DC%2BD387ovVGgtw%3D%3D 11922521
39. AA Vrij JM Jansen EJ Schoon A de Bruine HC Hemker RW Stockbrugger 2001 Low molecular weight heparin treatment in steroid refractory ulcerative colitis: Clinical outcome and influence on mucosal capillary thrombi Scand J Gastroenterol 234 Suppl 41 47 10.1080/003655201753265091
40. P Widlak WT Garrard 2006 The apoptotic endonuclease DFF40/CAD is inhibited by RNA, heparin and other polyanions Apoptosis 11 1331 1337 10.1007/s10495-006-6983-0 1:CAS:528:DC%2BD28Xms1Ohsrs%3D 16699957
41. RV Williams LL Minich LY Tani 2001 Pharmacological therapy for patients with Kawasaki disease Paediatr Drugs 3 649 660 10.2165/00128072-200103090-00003 1:STN:280:DC%2BD3MnjsFClsQ%3D%3D 11688596
42. RV Williams VM Wilke LY Tani LL Minich 2002 Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 109 E4 10.1542/peds.109.1.e4 11773572
43. RV Williams WY Tcheng L Minich 2004 Anticoagulation in the acute and long-term management of Kawasaki disease Prog Pediatr Cardiol 19 179 188 10.1016/j.ppedcard.2004.08.012